deltatrials
Active Not Recruiting INTERVENTIONAL NCT03192020

Trial Comparing Treatment Strategies in Dupuytren's Contracture (DETECT)

DupuytrEn Treatment EffeCtiveness Trial (DETECT): Needle Fasciotomy, Surgery or Collagenase Injection for Dupuytren's Contracture

Sponsor: Central Finland Hospital District

Updated 17 times since 2017 Last updated: Apr 28, 2026 Started: Sep 15, 2017 Primary completion: May 31, 2026 Completion: May 31, 2031
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03192020, this observational or N/A phase trial focuses on Dupuytren Contracture and remains ongoing. Sponsored by Central Finland Hospital District, it has been updated 17 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

Dupuytren's contracture (DC) is a fibroproliferative disorder of the palmar fascia, which in time leads to flexion contracture in one or more fingers. Etiology of the disease is still unknown, but it strongly seems that genetic factors play a major role. DC is associated most commonly with Caucasian population groups from Northern Europe. The estimated global prevalence among whites is 3% to 6% and increases with age. Men women ratio is 7:1. There is no definitive cure for DC. The treatment aims at relieving the symptoms by releasing the contracture by percutaneous or operative techniques. The investigators planned a prospective, randomized, controlled, outcome assessor-blinded, three armed parallel 1:1:1, multicenter trial comparing the cost-effectiveness of 1) collagenase clostridium histolyticum followed by limited fasciectomy in non-responsive cases, 2) percutaneous needle fasciotomy followed by limited fasciectomy in non-responsive cases and 3) primary limited fasciectomy in short- and long-term follow-up in DC. Protocol is approved by Tampere university hospital institutional review board and Finnish Medicine Agency (Fimea). All patients will give written informed consent. The results of the trial will be disseminated as published articles in peer-reviewed journals. Treatment of Duputren's contracture aims at reducing the functional deficit caused by the contracture. Recurrence is...

Dupuytren's contracture (DC) is a fibroproliferative disorder of the palmar fascia, which in time leads to flexion contracture in one or more fingers. Etiology of the disease is still unknown, but it strongly seems that genetic factors play a major role. DC is associated most commonly with Caucasian population groups from Northern Europe. The estimated global prevalence among whites is 3% to 6% and increases with age. Men women ratio is 7:1. There is no definitive cure for DC. The treatment aims at relieving the symptoms by releasing the contracture by percutaneous or operative techniques.

The investigators planned a prospective, randomized, controlled, outcome assessor-blinded, three armed parallel 1:1:1, multicenter trial comparing the cost-effectiveness of 1) collagenase clostridium histolyticum followed by limited fasciectomy in non-responsive cases, 2) percutaneous needle fasciotomy followed by limited fasciectomy in non-responsive cases and 3) primary limited fasciectomy in short- and long-term follow-up in DC.

Protocol is approved by Tampere university hospital institutional review board and Finnish Medicine Agency (Fimea). All patients will give written informed consent. The results of the trial will be disseminated as published articles in peer-reviewed journals.

Treatment of Duputren's contracture aims at reducing the functional deficit caused by the contracture. Recurrence is almost inevitable if the follow-up is long enough. Therefore, the investigators aim to analyze the effectiveness of three different treatment strategies in long-term follow-up, in addition to short-term follow-up, which include multiple interventions rather than just single intervention. The investigators chose a pragmatic primary outcome, which comprises both objective and subjective standpoint and reflects the needs of the patients as well as goals of the healthcare system. Furthermore, our short-term results give good high quality level evidence of effectiveness of all the three treatments and long-term follow-up a good perspective to the cost-effectiveness of the strategies.

Status Flow

~Jul 2017 – ~Nov 2017 · 4 months · monthly snapshot~Nov 2017 – ~May 2018 · 6 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Apr 2019 · 5 months · monthly snapshot~Apr 2019 – ~Sep 2020 · 17 months · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2022 · 15 months · monthly snapshot~Jun 2022 – ~Apr 2023 · 10 months · monthly snapshot~Apr 2023 – ~Apr 2024 · 12 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~May 2026 · 13 months · monthly snapshotMay 4, 2026 – present · 2 months · daily API

Change History

17 versions recorded
  1. May 4, 2026 — Present [daily]

    Active Not Recruiting

    Phase: PHASE4None

  2. Apr 2025 — May 2026 [monthly]

    Active Not Recruiting PHASE4

  3. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE4

  5. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE4

Show 12 earlier versions
  1. Apr 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE4

  2. Jun 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE4

  3. Mar 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE4

    Status: RecruitingActive Not Recruiting

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE4

  5. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE4

  6. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE4

  7. Apr 2019 — Sep 2020 [monthly]

    Recruiting PHASE4

  8. Nov 2018 — Apr 2019 [monthly]

    Recruiting PHASE4

  9. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE4

  10. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE4

  11. Nov 2017 — May 2018 [monthly]

    Recruiting PHASE4

    Status: Not Yet RecruitingRecruiting

  12. Jul 2017 — Nov 2017 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

Trial is a prospective, randomized, controlled, outcome assessor-blinded, three armed parallel 1:1:1, multicenter trial. The research objective is to determine, which treatment strategy 1) primary percutaneous needle fasciotomy (PNF) followed by surgical limited fasciectomy (LF) in patients who do not respond to PNF, 2) primary collagenase clostridium histolyticym (CCH) followed by LF in patients who do not respond to CCH or 3) LF as the primary (and secondary) treatment modality is the most cost-effective in treating Dupuytren´s contracture. Short- and long-term results will be published.

Contact Information

Sponsor contact:
  • Central Finland Hospital District
  • Finnish Institute for Health and Welfare
  • Helsinki University Central Hospital
  • Kuopio University Hospital
  • Medcare Oy
  • Orton Orthopaedic Hospital
  • Oulu University Hospital
  • Tampere University
  • Tampere University Hospital
  • Turku University Hospital
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .